Abbott India Ltd
ABBOTINDIAAbbott India Ltd
ABBOTINDIAPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
47.72 | 16.57 | 1.42% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast from 6 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Abbott India is a healthcare company engaged in pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,665.09 | 2,960.20 | 3,415.49 | 3,791.89 | 4,207.53 | 4,390.92 | 5,015.73 | 5,533.23 | 6,123.53 | 6,330.62 | ||||||||||
Raw Materials | 1,477.16 | 1,813.51 | 2,006.94 | 2,090.78 | 2,254.39 | 2,494.92 | 2,679.49 | 2,908.97 | 3,212.88 | 4,518.86 | ||||||||||
Power & Fuel Cost | 6.98 | 7.74 | 10.26 | 12.61 | 13.73 | 12.74 | 14.98 | 17.15 | 16.63 | |||||||||||
Employee Cost | 341.09 | 345.27 | 393.69 | 435.58 | 476.11 | 492.65 | 579.46 | 563.59 | 576.58 | |||||||||||
Selling & Administrative Expenses | 343.35 | 353.66 | 365.41 | 432.83 | 400.27 | 366.98 | 459.18 | 467.74 | 429.89 | |||||||||||
Operating & Other expenses | 81.54 | -14.93 | -2.30 | 102.07 | 192.19 | 21.27 | 117.69 | 216.00 | 186.18 | |||||||||||
EBITDA | 414.97 | 454.95 | 641.49 | 718.02 | 870.84 | 1,002.36 | 1,164.93 | 1,359.78 | 1,701.37 | 1,811.76 | ||||||||||
Depreciation/Amortization | 14.44 | 16.43 | 16.19 | 16.92 | 59.61 | 58.13 | 66.10 | 69.97 | 71.17 | 72.04 | ||||||||||
PBIT | 400.53 | 438.52 | 625.30 | 701.10 | 811.23 | 944.23 | 1,098.83 | 1,289.81 | 1,630.20 | 1,739.72 | ||||||||||
Interest & Other Items | 2.52 | 2.04 | 3.82 | 2.25 | 8.53 | 18.28 | 19.10 | 15.99 | 12.45 | 11.23 | ||||||||||
PBT | 398.01 | 436.48 | 621.48 | 698.85 | 802.70 | 925.95 | 1,079.73 | 1,273.82 | 1,617.75 | 1,728.49 | ||||||||||
Taxes & Other Items | 142.76 | 159.84 | 220.26 | 248.52 | 209.77 | 235.26 | 281.03 | 324.41 | 416.53 | 443.83 | ||||||||||
Net Income | 255.25 | 276.64 | 401.22 | 450.33 | 592.93 | 690.69 | 798.70 | 949.41 | 1,201.22 | 1,284.66 | ||||||||||
EPS | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 604.57 | ||||||||||
DPS | 35.00 | 40.00 | 55.00 | 65.00 | 250.00 | 275.00 | 275.00 | 325.00 | 410.00 | 410.00 | ||||||||||
Payout ratio | 0.29 | 0.31 | 0.29 | 0.31 | 0.90 | 0.85 | 0.73 | 0.73 | 0.73 | 0.68 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Abbott India Ltd | 51.03 | 16.57 | 1.42% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare ABBOTINDIA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Abbott India Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2994% | Percentage of the fund’s portfolio invested in the stock 2.78% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/86 (0) |
Axis Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7763% | Percentage of the fund’s portfolio invested in the stock 1.59% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/113 (0) |
Canara Robeco Emerging Equities - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7278% | Percentage of the fund’s portfolio invested in the stock 1.85% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/96 (+1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
ABBOTINDIA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 1.42%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.21 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 19, 2024
Dividend/Share
₹410.00
Ex DateEx Date
Jul 19, 2024
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹145.00
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹180.00
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateAug 2, 2022
Dividend/Share
₹145.00
Ex DateEx Date
Aug 2, 2022
Cash Dividend
Ex DateEx DateAug 2, 2022
Dividend/Share
₹130.00
Ex DateEx Date
Aug 2, 2022
According to the regulatory filing, the new vaccine provides broader protection against pneumococcal disease, covering 14 different serotypes (strains) of the bacteria, making it more comprehensive than the existing PCV-10 and PCV-13 vaccines. A conjugate vaccine is a distinct type of vaccine that combines a part of the bacteria with a protein to make it work better. This helps the immune system recognize and fight off the bacteria more effectively, making it stronger against certain infections, which can result in severe diseases, especially among children. Children under five years of age, especially those aged two years or under, face a high risk of pneumococcal disease, which is caused by a bacterial infection.i Pneumococcal infections can result in a range of conditions, including pneumonia, meningitis (inflammation of the tissues surrounding the brain and spinal cord), or blood infections, collectively known as Invasive Pneumococcal Disease (IPD). Vaccination can protect against some of these infections and can prevent complications in children. IPD is associated with high mortality in children under five years of age, resulting in 14% of deaths in India. The PCV-14 vaccine protects against five more strains than the PCV 10, and two more strains than the PCV 13 vaccines that are currently used in India, in private clinics and hospitals. The recommended immunization schedule for PneumoShield 14, which is administered via intramuscular injections, is at 6, 10, and 14 weeks. Swati Dalal, managing director, Abbott India, commented, 'Children, especially those under two years old, are at a higher risk of having pneumococcal disease. This can hinder their healthy growth and development and increase the risk of complications. This innovation offers broader protection potential against 14 pneumococcal strains in circulation, which cause the majority of pneumococcal-related diseases in India. Introducing this vaccine is another step in our commitment to further strengthen our pediatric portfolio, to help children stay healthy.' Vijay Yewale, Pediatrician, Yewale Hospital, Mumbai added, 'Immunization offers an important protective solution for parents to fight off pneumococcal-related diseases such as pneumonia and meningitis, especially among children. Considering the challenges in diagnosing and treating such diseases, there is a clear need for advanced vaccines with a wider representation of relevant pneumococcal bacteria strains. This in turn, helps provide broader protection against pneumococcal disease amongst children.' Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. The company's standalone net profit increased 14.6% to Rs 358.61 crore in Q2 FY25 as compared with Rs 312.94 crore in Q2 FY24. Revenue from operations was at Rs 1,632.67 crore in Q2 FY25, up 9.3% from Rs 1,632.67 crore reported in the same quarter previous year. The scrip shed 0.56% to Rs 27,350 on the BSE. Powered by Capital Market - Live
The Board of Abbott India at its meeting held on 07 November 2024 has approved the appointment of Sridhar Kadangode (DIN: 06715478) as an Additional Director of the Company with effect from 07 November 2024. Powered by Capital Market - Live
Net profit of Abbott India rose 14.59% to Rs 358.61 crore in the quarter ended September 2024 as against Rs 312.94 crore during the previous quarter ended September 2023. Sales rose 9.27% to Rs 1632.67 crore in the quarter ended September 2024 as against Rs 1494.14 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1632.671494.14 9 OPM %26.8925.49 - PBDT496.94433.26 15 PBT479.43415.42 15 NP358.61312.94 15 Powered by Capital Market - Live
Abbott India will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live
Abbott India announced the resignation of Ashok Saini as Commercial Director - GenNext, Vaccines and Neurolife of the Company, effective close of business hours of 16 October 2024. Powered by Capital Market - Live
The key equity indices further extended gains and hit fresh record highs in mid-morning trade. The Nifty scaled above the 25,700 level. Auto shares advanced for the second trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, climbed 967.25 points or 1.17% to 84,151.28. The Nifty 50 index advanced 278.65 points or 1.10% to 25,701.35. The Sensex and Nifty clocked an all-time high of 84,240.50 and 25,691.15, respectively in mid-morning trade. Further, the Nifty Bank also hit a life high of 53,559.35. In the broader market, the S&P BSE Mid-Cap index added 0.61% and the S&P BSE Small-Cap index advanced 1.11%. The market breadth was strong. On the BSE, 2,460 shares rose and 1,275 shares fell. A total of 148 shares were unchanged. Buzzing Index : The Nifty Auto index added 1.68% to 26,342.10. The index advanced 2.08% in two trading sessions. Mahindra & Mahindra (up 4.23%), Maruti Suzuki India (up 2.47%), Eicher Motors (up 2.11%), Bosch (up 1.52%) and TVS Motor Company (up 1.35%), Hero MotoCorp (up 1.11%), Exide Industries (up 0.71%), Bajaj Auto (up 0.57%), Bharat Forge (up 0.49%) and Balkrishna Industries (up 0.28%) edged higher. On the other hand, Samvardhana Motherson International (down 1.43%), Apollo Tyres (down 0.02%) edged lower. Stocks in Spotlight : Abbott India fell 0.22%. The company said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, under the brand name Vonefi. Shalby rallied 3.39% after the company announced that it has received a license to operate a Bone Bank at Krishna Shalby Hospital. Global Markets: Asian stocks traded higher on Friday after Wall Street soared overnight following the Federal Reserve's outsized rate cut. Bank of Japan keeps key interest rate steady as it treads cautiously on normalizing policy. The Bank of Japan kept its benchmark interest rate steady at 'around 0.25%', the highest rate since 2008 at the conclusion of a two-day meeting Friday. Japan's economy has recovered moderately, the central bank said in its official statement, while acknowledging 'some weakness has been seen in part.' BOJ said the country's core inflation rate, which strips out fresh food prices will rise through fiscal year 2025. Japan's Core CPI, excluding volatile fresh food prices, increased by 2.8% year-on-year in August, reaching a 10-month high. This figure was in line with expectations and up from the 2.7% recorded in the previous month. A core reading that excludes both fresh food and energy prices, closely watched by the BOJ as a gauge of underlying inflation, rose to 2% in August from 1.9% in the prior month. Headline CPI inflation reached a 10-month high of 3% in August, up from 2.8% in the previous month. In China, the central bank maintained its benchmark lending rates, disappointing hopes for immediate policy support to bolster its struggling economy. China also kept its key lending rates steady, with the one-year loan prime rate at 3.35% and the five-year LPR at 3.85%. US stocks surged to new all-time highs on Thursday, as markets welcomed the Federal Reserve's aggressive interest rate cut to protect the labor market. The S&P 500 gained 1.7%, reaching 5,713.64, while the tech-heavy Nasdaq Composite Index jumped 2.5% to 18,013.98. The Fed on Wednesday reduced its key lending rate by 0.50%, opting for a larger cut after considering a quarter-point move. Powered by Capital Market - Live
Vonoprazan (PCAB or potassium competitive acid blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the gastroesophageal reflux disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable the company, a leader in the gut health space, to enhance access to this novel therapy to more patients across India. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. The company's net profit jumped 41.1% to Rs 290.24 crore in Q1 FY24 as compared with Rs 205.64 crore in Q1 FY23. Revenue from operations was at Rs 1,479 crore in Q1 FY24, up 13.4% from Rs 1,304.12 crore reported in the same quarter previous year. Shares of Abbott India shed 0.51% to Rs 27,820.80 on the BSE.Powered by Capital Market - Live
Net profit of Abbott India rose 13.01% to Rs 328.01 crore in the quarter ended June 2024 as against Rs 290.24 crore during the previous quarter ended June 2023. Sales rose 5.32% to Rs 1557.61 crore in the quarter ended June 2024 as against Rs 1479.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1557.611479.00 5 OPM %25.1024.00 - PBDT455.59407.66 12 PBT437.22390.49 12 NP328.01290.24 13 Powered by Capital Market - Live
Abbott India will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live
Dexcom plunges as revenue forecast cut spooks investors
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.06%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.73% to 1.62%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 21.68%, vs industry avg of 15.27%